Why the study?
Do ACE inhibitors and nondihydropyridine calcium blockers improve renal and metabolic outcomes in patients with diabetes and hypertension compared to other antihypertensive therapies?
Population
Patients with diabetes, particularly those with a family history of cardiovascular disease or hypertension…
Comparison
Angiotensin-converting enzyme inhibitors… vs Other antihypertensive therapies
Design
Review
Authors
Loading...
May support ACE inhibitors and nondihydropyridine CCBs in diabetic nephropathy; leaves open confirmatory RCTs.
Do ACE inhibitors and nondihydropyridine calcium blockers improve renal and metabolic outcomes in patients with diabetes and hypertension compared to other antihypertensive therapies?
ACE inhibitors and nondihydropyridine calcium blockers offer specific renal and metabolic benefits in patients with diabetic nephropathy, highlighting the need for careful selection of antihypertensive therapy.
George L. Bakris (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: